Madiha Derouazi
Hoofd Techniek/Wetenschap/O&O bij AC IMMUNE SA
Vermogen: 7 271 $ op 30-04-2024
Oorsprong van het eerstegraads netwerk van Madiha Derouazi
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
21
| Public Company | Pharmaceuticals: Major | 21 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.
6
| Subsidiary | Biotechnology | 6 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Madiha Derouazi via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University of Lausanne | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
| MEDIGENE AG | Biotechnology | Chief Operating Officer Investor Relations Contact | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree Doctorate Degree | |
BioMedPartners AG
 BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Investment Managers | Chairman Private Equity Investor | |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member | |
| University of St. Gallen | College/University | Corporate Officer/Principal | |
| Swiss Institute for Empirical Economic Research | Director/Board Member | ||
| University of Bern | College/University | Undergraduate Degree | |
| University of Zurich | College/University | Undergraduate Degree | |
| World Demographic & Ageing Forum | Corporate Officer/Principal | ||
| Institute of Public Finance & Fiscal Law | Corporate Officer/Principal | ||
| Center for Disability & Integration | Corporate Officer/Principal | ||
| Network for Studies on Pensions Aging Retirement | Corporate Officer/Principal | ||
| CESifo Research Network | Corporate Officer/Principal | ||
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
| Swiss Federal Commission for Economic Issues | Corporate Officer/Principal | ||
| SCHINDLER HOLDING AG | Industrial Machinery | Director/Board Member | |
| SCHWEIZERISCHE NATIONALBANK | Major Banks | Director/Board Member | |
| HUBER+SUHNER AG | Telecommunications Equipment | Director/Board Member | |
| Swiss Institute For Intl Economics & Applied Economic Research | Chairman | ||
| Swiss Society of Economics & Statistics | President | ||
| Richard Büchner Foundation | Director/Board Member | ||
| University of Tilburg | College/University | Corporate Officer/Principal | |
| Gebert Rüf Stiftung | Corporate Officer/Principal | ||
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member | |
| BIOMÉRIEUX | Medical Specialties | Director of Finance/CFO | |
| Wuerzburg Schweinfurt University of Applied Sciences | College/University | Doctorate Degree | |
Nestlé USA, Inc.
 Nestlé USA, Inc. Agricultural Commodities/MillingProcess Industries Nestle USA, Inc. produces dairy and bakery products. Its products include chocolate and confectionaries, beverages, ice cream, juices, milk products, pet food, prepared foods, and sports nutrition. The company is headquartered in Arlington, VA. | Agricultural Commodities/Milling | Corporate Officer/Principal | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member | |
| SYMRISE AG | Chemicals: Specialty | Director/Board Member | |
BioMedInvest AG I
 BioMedInvest AG I Investment ManagersFinance BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million. | Investment Managers | Chairman | |
AB2 Bio SA
 AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
Inventages II
 Inventages II Investment ManagersFinance Inventages II invests in companies located in Bahamas. The fund focus on companies such as life science and consumer applications. It provides financing for seed, early and buyout capital requirements. | Investment Managers | Founder | |
Nestlé Nespresso SA
 Nestlé Nespresso SA Industrial MachineryProducer Manufacturing Nestlé Nespresso SA designs and manufactures espresso machines. The company was founded in 1986 and is headquartered in Zurich, Switzerland. | Industrial Machinery | Corporate Officer/Principal | |
| Université Paris Dauphine-PSL | College/University | Graduate Degree | |
| ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Max Schmidheiny-Stiftung | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| University of Milan | College/University | Doctorate Degree | |
Dimerix Bioscience Pty Ltd.
 Dimerix Bioscience Pty Ltd. Medical DistributorsDistribution Services Dimerix Bioscience Pty Ltd. engages in the development and commercialization of drug therapies and drug discovery tools. It deals with clinical research organizations to progress its programs through clinical studies. It focuses on the clinical development of its therapeutic product DMX200 which is targeted to treat patients with chronic kidney disease. The company was founded by James Howard Williams on December 16, 2004 and is headquartered in Melbourne, Australia. | Medical Distributors | Chief Executive Officer | |
| DIMERIX LIMITED | Pharmaceuticals: Major | Director/Board Member | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member | |
Acousia Therapeutics GmbH
 Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member | |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member | |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Director/Board Member | |
T3 Pharmaceuticals AG
 T3 Pharmaceuticals AG BiotechnologyHealth Technology T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Zwitserland | 27 |
| Duitsland | 9 |
| Frankrijk | 4 |
| België | 3 |
| Nederland | 3 |
Sectoraal
| Health Technology | 16 |
| Consumer Services | 10 |
| Finance | 7 |
| Commercial Services | 3 |
| Producer Manufacturing | 3 |
Operationeel
| Director/Board Member | 87 |
| Corporate Officer/Principal | 59 |
| Chief Tech/Sci/R&D Officer | 20 |
| Independent Dir/Board Member | 19 |
| Doctorate Degree | 16 |
Sterkste connecties
| Insiders | |
|---|---|
| Monika Bütler | 25 |
| Douglas Williams | 25 |
| Karin Hehenberger | 21 |
| Roberto de Ponti | 16 |
| Werner Lanthaler | 13 |
| Johanna Holldack | 11 |
| Andrea Pfeifer | 11 |
| Frank Kalkbrenner | 11 |
| Andreas Wallnöfer | 10 |
| Carl June | 9 |
| Gary Waanders | 8 |
| Monica Shaw | 8 |
| Marie Kosco-Vilbois | 7 |
| Sonia Maria Poli | 7 |
| Roy Ervin Twyman | 6 |
- Beurs
- Insiders
- Madiha Derouazi
- Bedrijfsconnecties